AbbVie Inc. ABBV NYSE

AbbVie Inc. (ABBV) reported total assets of $133.96B and total liabilities of $137.19B for fiscal year 2025, resulting in total equity of $-3.23B.

The company held $5.26B in cash and short-term investments. Total debt stood at $69.07B, with net debt of $63.84B. The Debt-to-Equity (D/E) ratio was -21.4 (conservative).

Current ratio is 0.67, which may signal tight short-term liquidity. Interest coverage is 8.1x (strong).

Criteria supported by this page:

• HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (94/100) — Total assets $133.96B and equity $-3.23B support the company's competitive scale
• VALUE (38/100) — Debt-to-Equity -21.4 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 61/100 with 3/7 criteria passed.

LLY

Eli Lilly and Company

$922.50

-0.76%

JNJ

Johnson & Johnson

$240.10

+0.90%

AZN

AstraZeneca PLC

$204.38

+1.06%

MRK

Merck & Co., Inc.

$119.96

-0.16%

NVS

Novartis AG

$153.38

-0.71%

UNH

UnitedHealth Group Incorporated

$314.19

+0.38%

AMGN

Amgen Inc.

$350.95

+0.32%

NVO

Novo Nordisk A/S

$39.32

+3.53%